ZA200900743B - Protein kinase C activity enhancer containing alkyl ether derivative or salt thereof - Google Patents
Protein kinase C activity enhancer containing alkyl ether derivative or salt thereofInfo
- Publication number
- ZA200900743B ZA200900743B ZA200900743A ZA200900743A ZA200900743B ZA 200900743 B ZA200900743 B ZA 200900743B ZA 200900743 A ZA200900743 A ZA 200900743A ZA 200900743 A ZA200900743 A ZA 200900743A ZA 200900743 B ZA200900743 B ZA 200900743B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- protein kinase
- salt
- alkyl ether
- ether derivative
- Prior art date
Links
- 102000003923 Protein Kinase C Human genes 0.000 title abstract 4
- 108090000315 Protein Kinase C Proteins 0.000 title abstract 4
- 239000003623 enhancer Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- 150000005215 alkyl ethers Chemical class 0.000 title 1
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- -1 benzothiophene alkyl ether Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006212722 | 2006-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200900743B true ZA200900743B (en) | 2010-05-26 |
Family
ID=38997281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200900743A ZA200900743B (en) | 2006-08-04 | 2007-08-02 | Protein kinase C activity enhancer containing alkyl ether derivative or salt thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8173633B2 (xx) |
| EP (1) | EP2048145B9 (xx) |
| JP (1) | JP5255441B2 (xx) |
| KR (1) | KR20090038471A (xx) |
| CN (1) | CN101501026B (xx) |
| AT (1) | ATE491705T1 (xx) |
| AU (1) | AU2007279673B2 (xx) |
| BR (1) | BRPI0715056A2 (xx) |
| CA (1) | CA2659835A1 (xx) |
| CY (1) | CY1111691T1 (xx) |
| DE (1) | DE602007011281D1 (xx) |
| DK (1) | DK2048145T3 (xx) |
| ES (1) | ES2355768T3 (xx) |
| IL (1) | IL196754A0 (xx) |
| MX (1) | MX2009001255A (xx) |
| NO (1) | NO20090214L (xx) |
| NZ (1) | NZ574551A (xx) |
| PL (1) | PL2048145T3 (xx) |
| PT (1) | PT2048145E (xx) |
| SI (1) | SI2048145T1 (xx) |
| WO (1) | WO2008016107A1 (xx) |
| ZA (1) | ZA200900743B (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO122203B1 (ro) | 2001-10-19 | 2009-02-27 | Toyama Chemical Co., Ltd. | Derivaţi de alchil eter şi sărurile acestora |
| NZ574551A (en) * | 2006-08-04 | 2012-03-30 | Toyama Chemical Co Ltd | Use of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol (T-817) and it derivatives for the treatment of conditions such as cancer, tumour and glucose metabolism |
| ES2465005T3 (es) * | 2008-05-28 | 2014-06-04 | Toyama Chemical Co., Ltd. | Derivado de óxido de benzotiofeno y sus sales |
| BR112014011254A2 (pt) | 2011-11-11 | 2017-05-16 | Pfizer | 2-tiopirimidinonas |
| CN104159583B (zh) * | 2012-02-22 | 2018-04-13 | 富山化学工业株式会社 | 含有1‑(3‑(2‑(1‑苯并噻吩‑5‑基)乙氧基)丙基)氮杂环丁烷‑3‑醇或其盐的固体药物组合物 |
| JP6761413B2 (ja) * | 2015-06-11 | 2020-09-23 | 富士フイルム富山化学株式会社 | シグマ受容体結合剤 |
| DK3395342T3 (da) * | 2015-12-25 | 2020-10-12 | Fujifilm Toyama Chemical Co Ltd | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf |
| JP7057286B2 (ja) * | 2016-12-28 | 2022-04-19 | 富士フイルム富山化学株式会社 | 医薬組成物 |
| WO2018124284A1 (ja) * | 2016-12-28 | 2018-07-05 | 富山化学工業株式会社 | 医薬組成物 |
| US20190343796A1 (en) * | 2016-12-28 | 2019-11-14 | Fujifilm Toyama Chemical Co., Ltd. | Composition for external use |
| JP7079209B2 (ja) | 2016-12-28 | 2022-06-01 | 富士フイルム富山化学株式会社 | 医薬組成物およびその製造方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09507846A (ja) | 1993-12-30 | 1997-08-12 | スミスクライン・ビーチャム・コーポレイション | フェニルメチルヘキサンアミドおよびその使用 |
| EP1254898A4 (en) | 2000-01-26 | 2003-03-12 | Ono Pharmaceutical Co | BENZO-CONDENSED HETEROCYCLIC DERIVATIVES AND THESE MEDICINES CONTAINING ACTIVE SUBSTANCES |
| JP4303435B2 (ja) * | 2001-02-26 | 2009-07-29 | 富山化学工業株式会社 | ミトコンドリア機能賦活剤 |
| RO122203B1 (ro) * | 2001-10-19 | 2009-02-27 | Toyama Chemical Co., Ltd. | Derivaţi de alchil eter şi sărurile acestora |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| ES2379948T3 (es) * | 2002-06-14 | 2012-05-07 | Toyama Chemical Co., Ltd. | Composición medicinal que comprende Tacrine o Donepezil para mejorar la función cerebral |
| MX349134B (es) * | 2003-01-23 | 2017-07-12 | Esperion Therapeutics Inc | Compuestos de hidroxilo y composiciones para el manejo del colesterol y usos relacionados. |
| NZ543100A (en) * | 2003-04-17 | 2008-07-31 | Toyama Chemical Co Ltd | Preventive/remedy for retinal nerve dieases containing alkyl ether derivatives or salts thereof |
| SE529122C2 (sv) * | 2004-09-24 | 2007-05-02 | Jokab Safety Ab | Skyddsanordning för områdesbegränsning och övervakning |
| EP1864978A4 (en) * | 2005-03-28 | 2009-07-01 | Toyama Chemical Co Ltd | PROCESS FOR PRODUCING 1- (3- (2- (1-BENZOTHIOPHEN-5-YL) -ETHOXY) PROPYL) AZETIDIN-3-OL OR ITS SALTS |
| JP4902247B2 (ja) * | 2005-04-08 | 2012-03-21 | 富山化学工業株式会社 | ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体 |
| SI2011796T1 (sl) * | 2006-04-26 | 2015-02-27 | Toyama Chemical Co., Ltd. | Induktor nevrogeneze ali terapevtska uäśinkovina proti nevropatiji, vsebujoäśa derivat alkilnega etra ali sol le-tega |
| NZ574551A (en) * | 2006-08-04 | 2012-03-30 | Toyama Chemical Co Ltd | Use of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol (T-817) and it derivatives for the treatment of conditions such as cancer, tumour and glucose metabolism |
-
2007
- 2007-08-02 NZ NZ574551A patent/NZ574551A/en unknown
- 2007-08-02 JP JP2008527788A patent/JP5255441B2/ja not_active Expired - Fee Related
- 2007-08-02 EP EP07791845A patent/EP2048145B9/en not_active Not-in-force
- 2007-08-02 PT PT07791845T patent/PT2048145E/pt unknown
- 2007-08-02 DK DK07791845.6T patent/DK2048145T3/da active
- 2007-08-02 SI SI200730516T patent/SI2048145T1/sl unknown
- 2007-08-02 MX MX2009001255A patent/MX2009001255A/es active IP Right Grant
- 2007-08-02 ES ES07791845T patent/ES2355768T3/es active Active
- 2007-08-02 AT AT07791845T patent/ATE491705T1/de active
- 2007-08-02 PL PL07791845T patent/PL2048145T3/pl unknown
- 2007-08-02 WO PCT/JP2007/065165 patent/WO2008016107A1/ja active Application Filing
- 2007-08-02 CN CN2007800291310A patent/CN101501026B/zh not_active Expired - Fee Related
- 2007-08-02 ZA ZA200900743A patent/ZA200900743B/xx unknown
- 2007-08-02 KR KR1020097003927A patent/KR20090038471A/ko not_active Application Discontinuation
- 2007-08-02 CA CA002659835A patent/CA2659835A1/en not_active Abandoned
- 2007-08-02 DE DE602007011281T patent/DE602007011281D1/de active Active
- 2007-08-02 US US12/376,296 patent/US8173633B2/en not_active Expired - Fee Related
- 2007-08-02 AU AU2007279673A patent/AU2007279673B2/en not_active Ceased
- 2007-08-02 BR BRPI0715056-3A patent/BRPI0715056A2/pt not_active IP Right Cessation
-
2009
- 2009-01-14 NO NO20090214A patent/NO20090214L/no not_active Application Discontinuation
- 2009-01-27 IL IL196754A patent/IL196754A0/en unknown
-
2011
- 2011-02-14 CY CY20111100176T patent/CY1111691T1/el unknown
- 2011-06-17 US US13/163,105 patent/US20110245228A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2048145B9 (en) | 2011-05-04 |
| EP2048145A1 (en) | 2009-04-15 |
| CA2659835A1 (en) | 2008-02-07 |
| EP2048145A4 (en) | 2009-09-09 |
| DK2048145T3 (da) | 2011-04-04 |
| SI2048145T1 (sl) | 2011-04-29 |
| MX2009001255A (es) | 2009-06-12 |
| JPWO2008016107A1 (ja) | 2009-12-24 |
| CN101501026A (zh) | 2009-08-05 |
| AU2007279673B2 (en) | 2012-04-19 |
| US8173633B2 (en) | 2012-05-08 |
| CY1111691T1 (el) | 2015-10-07 |
| WO2008016107A1 (fr) | 2008-02-07 |
| JP5255441B2 (ja) | 2013-08-07 |
| AU2007279673A1 (en) | 2008-02-07 |
| US20110245228A1 (en) | 2011-10-06 |
| ATE491705T1 (de) | 2011-01-15 |
| PL2048145T3 (pl) | 2011-09-30 |
| US20100184997A1 (en) | 2010-07-22 |
| NO20090214L (no) | 2009-01-30 |
| PT2048145E (pt) | 2011-01-14 |
| KR20090038471A (ko) | 2009-04-20 |
| CN101501026B (zh) | 2012-04-04 |
| DE602007011281D1 (de) | 2011-01-27 |
| ES2355768T3 (es) | 2011-03-30 |
| NZ574551A (en) | 2012-03-30 |
| EP2048145B1 (en) | 2010-12-15 |
| BRPI0715056A2 (pt) | 2013-05-28 |
| IL196754A0 (en) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL196754A0 (en) | Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof | |
| MX2008013728A (es) | Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo. | |
| TNSN07397A1 (en) | Acetylene derivatives | |
| TW200640885A (en) | Novel haoalkanesulfonylaniline derivatives, weed killer and the use methods thereof | |
| ATE388146T1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
| IL204621A (en) | Amino Acid Derivatives - γ - In bicycles preparations containing them and their uses | |
| EP1857446A4 (en) | NEW HSP90 INHIBITOR | |
| WO2008108386A1 (ja) | 医薬組成物 | |
| TW200726753A (en) | 2,4-diamino-pyrimidines as aurora inhibitors | |
| WO2005111002A3 (de) | Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen | |
| WO2006100082A3 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
| MX2010013275A (es) | Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano. | |
| PH12015501098A1 (en) | Antituberculous composition comprising oxazole compounds | |
| ATE524181T1 (de) | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen | |
| WO2008010048A3 (en) | Novel 2-substituted methyl penam derivatives | |
| GEP20074256B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| TW200602344A (en) | Novel pyrrolo(2, 3-b)pyridine derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
| DE60314381D1 (de) | Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren | |
| GEP20115240B (en) | Indole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| MXPA04000036A (es) | Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht. | |
| CY1114378T1 (el) | Μεθοδος χρησιμοποιησης συνδυασμου παραγωγου βενζοφαινονης ή αλατος αυτου και ανοσοκατασταλτικου παραγοντα, και φαρμακευτικη συνθεση που περιλαμβανει αυτα τα συστατικα | |
| EP1908755A4 (en) | THERAPEUTIC AGENT AGAINST RESTENOSIS | |
| MY140963A (en) | Phenylpyridylpiperazine compounds | |
| BRPI0912266B8 (pt) | composto derivado de óxido de benzotiofeno, e, composição farmacêutica |